GSK (LON:GSK) Stock Rating Reaffirmed as “Buy” by Jefferies Financial Group

GSK (LON:GSK)‘s stock had its “buy” rating reaffirmed by analysts at Jefferies Financial Group in a report issued on Tuesday, Digital Look reports. They presently have a GBX 2,500 target price on the stock. Jefferies Financial Group’s price target points to a potential upside of 34.34% from the stock’s current price.

Other research analysts have also issued reports about the stock. Berenberg Bank increased their target price on shares of GSK from GBX 2,000 to GBX 2,200 and gave the stock a “hold” rating in a research note on Tuesday, September 15th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a research note on Tuesday, September 29th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 1,975 price target on shares of GSK in a research note on Tuesday, September 8th. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, GSK presently has a consensus rating of “Hold” and a consensus target price of GBX 2,064.38.

GSK Trading Up 0.3%

LON GSK opened at GBX 1,861 on Tuesday. The firm has a market capitalization of £74.57 billion, a PE ratio of 15.80, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The business’s 50-day moving average price is GBX 1,845.67 and its two-hundred day moving average price is GBX 1,924.07. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. GSK has a 12 month low of GBX 1,592 and a 12 month high of GBX 2,282.

GSK (LON:GSK) last posted its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. On average, analysts expect that GSK will post 175.98 EPS for the current year.

Insider Buying and Selling at GSK

In other news, insider Anne Beal acquired 637 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was purchased at an average price of GBX 4,985 per share, for a total transaction of £31,754.45. Also, insider Jonathan Symonds bought 1,500 shares of GSK stock in a transaction dated Friday, September 18th. The stock was acquired at an average cost of GBX 1,881 per share, with a total value of £28,215. In the last quarter, insiders bought 2,151 shares of company stock valued at $6,021,921. Company insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.